Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the italian oncology group for clinical research (GOIRC)

International Journal of Cancer

Volumn 87, Issue 5, 2000, Pages 724-727

  Boni, C ^a,f   Bisagni, G ^a   Savoldi, L ^a   Moretti, G ^a   Rondini, E ^a   Sassi, M ^a   Zadro, A ^a   De Pas, T ^b   Franciosi, V ^c   Pazzola, A ^d   Vignoli, R ^e   Banzi, M C ^a   Pajetta, V ^a  

^a Medical Oncology Service   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d SS Annunziata Hospital   (Italy)

^e Ospedale S Anna   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; MESNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DNA REPAIR; DRUG EFFECT; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0033861564     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000901)87:5<724::AID-IJC15>3.0.CO;2-N     Document Type: Article

References (29)

1. ABRATT, R.P., BEZWODA, W.R., FALKSON, G., GOEDHALS, L., HACKING, D. and RUGG, T.A., Efficacy and safety profile of gemcitabine in NSCLC: a phase II study. J. Clin. Oncol., 12, 1535-1540 (1994).
2. ANDERSON, H., LUND, B., BACH F., THATCHER, N., WALLING, J., and HANSEN, H.H., Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 12, 1821-1826 (1994).
3. BALDINI, E., TIBALDI, C., CHELLA, A., ET AL., Phase II study of vinorelbine/ ifosfamide/cisplatin for the treatment of advanced non-small cell lung cancer. Ann. Oncol., 7, 747-749 (1996).
4. BARNETO, I.C., DE LA HABA, J., GOSALBEZ, B., ARTAL, A., ANTON, A., ARANDA, E., Phase II activity of cisplatin (CDDP) plus ifosfamide (IFO) and gemcitabine (GEM) in non small cell lung cancer (NSCLC): preliminary results. Acts of the 8th World Conference on Lung Cancer, Dublin 18, 204 (abstract) (1997).
5. BERGER, D.P., FIEBIG, H.H., WINTERHALTER, B.R., WALLBRECHER, E., and HENSS, H., Preclinical phase II study of Ifosfamide in human tumor xenografts in vivo. Cancer Chemother. Pharmacol., 26, 7-11 (1990).
6. BRAAKHUIS, B.J.M., RUIZ VAN HAPEREN, V.W.T., BERGMAN, A.M., WELTERS, M.J.P., and PETERS, G.J., Preclinical in vivo evaluation of the combination of 2,3 difluorodeoxycytidine (dFdC, gemcitabine) and cisplatin (CDDP). Ann. Oncol., 5, 82 (Abstract 054) (1994).
7. CRINÒ, L., CLERICI, M., FIGOLI, F., ET AL., Chemotherapy of advanced non small cell lung cancer: a comparison of three active regimens: a randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann. Oncol., 6, 347-353 (1995).
8. CRINÒ, L., SCAGLIOTTI, G., MARANGOLO, M., ET AL., Cisplatin- Gemcitabine combination in advanced non small cell lung cancer: a phase II study. J. Clin. Oncol., 15, 297-303 (1997).
9. CRINÒ, L., SCAGLIOTTI, G., RICCI, S., ET AL., Gemcitabine - Cisplatin versus Mitomycin C - Ifosfamide - Cisplatin in advanced non small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol., 17, 3522-3530 (1999).
10. CULLEN, M.H., JOSHI, R., CHETIYAWARDANA, A.D., and WOODROFFE, C.M., Mitomycin, Ifosfamide and Cis-platin in non small cell lung cancer: Treatment good enough to compare. Brit. J. Cancer, 58, 359-361 (1988).
11. DE LAS PENAS, R., BUSQUIER, I., MUNARRIZ, J., ET AL., Phase II study of Gemcitabine, Ifosfamide and Cisplatin (GIP) in patients with advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 9, 88 (abstract 4249) (1998).
12. DEPIERRE, A., LEMARIÉ, E., DABOUIS, G., ET AL., A PHASE II STUDY OF NAVELBINE (VINORELBINE) IN THE TREATMENT OF NON SMALL CELL LUNG CANCER. Amer. J. Clin. Oncol., 14, 115-119 (1991).
13. FOSSELLA, F.V., LEE, J.S., MURPHY, W.K., ET AL., Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol., 12, 1238-1244 (1994).
14. FUJITA, F., FUJITA, M., and SAKAMOTO, Y., Antitumor activity of combination treatment combining gemcitabine with cisplatin or vindesine against human lung cancer xenografted in nude mice. Jap. J. Cancer Chemotherapy. 21, 2595-2601 (1994).
15. GOLDIN, A. Ifosfamide in experimental systems. Semin Oncol., 9, 14-23 (1982).
16. HAINSWORTH, J.D., THOMPSON, D.S., and GRECO, A., Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J. Clin. Oncol., 13, 1609-1614 (1995).
17. HERBST, R.S., DANG, N.H., SKARIN, A.T., Chemotherapy for Non Small Cell Lung Cancer. Hematol. Oncol. Clin. North Amer., 11, 473-517 (1997).
18. HUANG, P., CHUBB, S., HERTEL, L.W., GRINDEY, G.B., PLUNKETT, W., ET AL., Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51, 6119-6127 (1991).
19. JOHNSON, D.H., Overview of ifosfamide in small cell- and non-small-cell lung cancer. Semin. Oncol., 6, 87-98 (1990).
20. MILLER, A.B., HOOGSTRATEN, B., and STAQUET, M. Reporting results of cancer treatment. Cancer, 47, 207-214 (1981).
21. MOHEDANO, N., MEDINA, M.B., SANCHEZ, P., ET AL., Phase II trial of gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer. Acts of the 8th World Conference on Lung Cancer, Dublin, 18, 159 (abstract) (1997).
22. NON SMALL CELL LUNG CANCER COOPERATIVE GROUP, Chemotherapy in non small cell lung cancer: a meta analysis using updated data on individual patient data from 52 randomised clinical trials. Brit. Med. J., 311, 899-909 (1995).
23. PETERS, G.J., BERGMAN, A.M., RUIZ VAN HAPEREN, V.W.T., VEERMAN, G., KUIPER, C.M., and BRAAKHUIS, B.J., Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol., 22, 72-79 (1995).
24. PLUNKETT, W., GANDHI, V., and CHUBB, S., 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides 8, 775-785 (1989).
25. SCULIER, J.P., PAESMANS, M., THIRIAUX, J., ET AL., Phase III randomized trial comparing Cisplatin and Carboplatin with or without Ifosfamide in patients with advanced Non Small cell Lung Cancer. J. Clin. Oncol., 16, 1388-1396 (1998).
26. SHEPHERD, F.A., ANGLIN, G., ABRATT, R., ET AL., Influence of Gemcitabine (GEM) and Cisplatin (CP) schedule on response and survival in advanced non-small cell lung cancer (NSCLC). Proc. Amer. Soc. Clin. Oncol., 17, 472 (abstract 1816) (1998).
27. SOUQUET, P.J., FOURNEL, P., BOHAS, C.H., FORTUNE, I.C., and CHATTE, G., Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small cell lung cancer. Semin. Oncol., 23, 8-10 (1996)
28. TAN, E.H., ANG, P.T., WEE, J., FONG, K.W., LEONG, S.S., and KHOO, K.S., Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer. Acta Oncol., 38, 619-622 (1999).
29. VADELL, C., CARLES, J., GALLEN, M., ET AL., Gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of advanced non-small cell lung cancer. A phase II trial. Acts of the 8th World Conference on Lung Cancer, Dublin 18, 215 (abstract) (1997).